Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377669 | 0.77 | HDAC6 (0.49) | KCNH2HRH3POLBHDAC6ACHE | |
| SCHEMBL7449374 | 0.74 | CCR3 (0.60) | MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL5733936 | 0.71 | HDAC6 (0.52) | KCNH2HRH3POLBHDAC6 | |
| SCHEMBL7078849 | 0.71 | GAA (0.49) | SIGMAR1ACHE | |
| SCHEMBL24076759 | 0.71 | SLC6A2 (0.61) | SLC6A2SLC6A4 | |
| SCHEMBL30301400 | 0.71 | SLC6A2 (0.61) | SLC6A2SLC6A4 | |
| SCHEMBL9591405 | 0.70 | MEN1 (0.56) | POLBMEN1KMT2A | |
| SCHEMBL5823619 | 0.70 | MCL1 (0.62) | POLBHTR4ALDH1A1 | |
| SCHEMBL5377677 | 0.69 | GAA (0.50) | SIGMAR1KCNH2HRH3HDAC6ACHE | |
| SCHEMBL5732389 | 0.69 | GAA (0.50) | SIGMAR1KCNH2HRH3HDAC6ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073699-A1 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6130235-A | PIPERIDINE MOIETIES COUPLED TO INDOLE, BENZIMIDAZOLE OR BENZOTRIAZOLE. | SCIOS INC. (US) | 2000-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073699-A1 | Compounds and methods to treat cardiac failure and other disorders | RCOR1, NR3C2, CNR1 | SIGMAR1 61/4885KCNH2 1160/4885HRH3 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.